Generic Orilissa Availability

Last updated on Sep 11, 2024.

Orilissa is a brand name of elagolix, approved by the FDA in the following formulation(s):

ORILISSA (elagolix sodium - tablet;oral)

• Manufacturer: ABBVIE
  Approval date: July 23, 2018
  Strength(s): EQ 150MG BASE ^[RLD], EQ 200MG BASE ^[RLD]

Has a generic version of Orilissa been approved?

No. There is currently no therapeutically equivalent version of Orilissa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Orilissa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods of administering elagolix
  Patent 10,537,572
  Issued: January 21, 2020
  Inventor(s): Goss Sandra L. & Klein Cheri E. & Ng Juki Wing-Keung & Salem Ahmed
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

  Patent expiration dates:

  • September 1, 2036
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN
• Methods of administering elagolix
  Patent 10,682,351
  Issued: June 16, 2020
  Inventor(s): Goss Sandra L. & Klein Cheri E. & Ng Juki Wing-Keung & Salem Ahmed
  Assignee(s): ABBVIE INC.
  

  The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

  Patent expiration dates:

  • September 1, 2036
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE
• Patent 11,344,551
  

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN TO REDUCE DYSMENORRHEA AND NON-MENSTRUAL PELVIC PAIN
  • March 14, 2034
    
    ✓ 
    Patent use: USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN HAVING DYSPAREUNIA ASSOCIATED WITH ENDOMETRIOSIS
• Patent 11,542,239
  

  Patent expiration dates:

  • July 23, 2039
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Patent 11,690,845
  

  Patent expiration dates:

  • August 27, 2040
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG OR 200 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE
• Patent 11,690,854
  

  Patent expiration dates:

  • April 19, 2038
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN A PATIENT WITH MODERATE HEPATIC IMPAIRMENT
• Patent 11,707,464
  

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX FOR UP TO 24 MONTHS
• Patent 7,056,927
  

  Patent expiration dates:

  • September 10, 2024
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Patent 7,176,211
  

  Patent expiration dates:

  • July 6, 2024
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
• Patent 7,419,983
  

  Patent expiration dates:

  • July 6, 2029
    
    ✓ 
    Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
    ✓ 
    Drug substance
    ✓ 
    Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer